These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2889256)

  • 41. Frequent non-response to histamine H2-receptor antagonists in cirrhotics.
    Walker S; Krishna DR; Klotz U; Bode JC
    Gut; 1989 Aug; 30(8):1105-9. PubMed ID: 2570008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Accelerated healing of ulcus ventriculi by a single evening dose of famotidine. Results of an Austrian-German-Italian multicenter study].
    Dammann HG; Barbara L; Bianchi-Porro G; Cheli R; Hentschel E; Müller P; Paoluzzi P; Simon B; Walter TA
    Schweiz Med Wochenschr; 1985 Apr; 115(14):484-8. PubMed ID: 2859653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
    Hu FL; Jia JC; Li YL; Yang GB
    J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease.
    Gitlin N; McCullough AJ; Smith JL; Mantell G; Berman R
    Gastroenterology; 1987 Jan; 92(1):48-53. PubMed ID: 2877912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Central nervous system reactions associated with famotidine: report of five cases.
    Odeh M; Oliven A
    J Clin Gastroenterol; 1998 Oct; 27(3):253-4. PubMed ID: 9802455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
    Bianchi Porro G
    Digestion; 1985; 32 Suppl 1():62-9. PubMed ID: 2866137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Famotidine in the USA: a review of efficacy studies.
    Gitnick G
    J Int Med Res; 1989; 17 Suppl 1():17A-24A. PubMed ID: 2566539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
    Taha AS; McCloskey C; Prasad R; Bezlyak V
    Lancet; 2009 Jul; 374(9684):119-25. PubMed ID: 19577798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [I.v. famotidine versus i.v. ranitidine: intragastric pH behavior in surgical intensive care patients].
    Friedl W; Krier C; Dammann HG; Müller P; Simon B
    Z Gastroenterol; 1985 Nov; 23(11):603-7. PubMed ID: 2868579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Famotidine in the treatment of duodenal ulcers resistant to other histamine H2-receptor antagonists.
    Chen PH; Wang TH; Wang CY; Chen CY; Cheng TC; Tsai YT; Siauw CP; Yang KC; Chen GH; Sung JL
    J Int Med Res; 1989; 17 Suppl 1():25A-31A. PubMed ID: 2566541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease.
    Kamada T; Hata J; Kusunoki H; Sugiu K; Ito M; Tanaka S; Kawamura Y; Chayama K; Haruma K
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():99-104. PubMed ID: 15943855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multicenter, randomized, double-blind study comparing famotidine with cimetidine in the treatment of active duodenal ulcer disease.
    Rodrigo L; Viver J; Conchillo F; Barrio E; Forné M; Zozaya JM; Alvarez A; Dieguez P; Muñoz M; Panés J
    Digestion; 1989; 42(2):86-92. PubMed ID: 2570005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Famotidine. Pharmacologic and clinical profile of the new histamine H2 receptor antagonist].
    Müller P; Dammann HG; Simon B
    Fortschr Med; 1986 Apr; 104(15):319-22. PubMed ID: 2872147
    [No Abstract]   [Full Text] [Related]  

  • 55. Action of famotidine and ranitidine on prostaglandin E2 (PGE2) content of fundic and duodenal mucosa in duodenal ulcer patients.
    Lezoche E; Vagni V; D'Alessandro MD; Mariani P; Carlei F; Lomanto D; Nardovino M; Martelli A; Speranza V
    Drugs Exp Clin Res; 1987; 13(10):655-8. PubMed ID: 2892658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety profile of H2-receptor antagonists: current status of famotidine.
    Levine JB
    J Int Med Res; 1989; 17 Suppl 1():48A-53A. PubMed ID: 2566543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peptic ulceration.
    Weir DG
    Br Med J (Clin Res Ed); 1988 Jan; 296(6616):195-200. PubMed ID: 2892567
    [No Abstract]   [Full Text] [Related]  

  • 58. Famotidine: an appraisal of its mode of action and safety.
    Berlin RG; Clineschmidt BV; Majka JA
    Am J Med; 1986 Oct; 81(4B):8-12. PubMed ID: 2877577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recurrent parotitis with H2 receptor antagonists in a patient with Sjogren's syndrome.
    Tomasko MA; Luskin AT
    Am J Med; 1988 Aug; 85(2):271. PubMed ID: 2899973
    [No Abstract]   [Full Text] [Related]  

  • 60. Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study.
    Kinoshita Y; Chiba T;
    J Gastroenterol; 2012 Apr; 47(4):377-86. PubMed ID: 22183857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.